Monographie - Folinate calcium

Utolsó frissítés :
28/04/2024

Folinate calcium

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Antrex	Finnország
Axifolin	Németország
Bendafolin	Egyiptom, Irán
Biofolic	Olaszország
Calcium leucovorin	Törökország
Calfolex	Olaszország
Citofolin	Olaszország
Cromaton	Luxemburg
Dalisol	Colombia, India, Mexikó
Degalin	Németország
Durofolin	Görögország
Etamolin	Peru
Eurofolic	Németország
Fastovorin	India
Folcasin	Románia
Folical	Colombia
Folidan	Spanyolország
Folinate de calcium	Franciaország
Furoic	Olaszország
Innefol	Mexikó
Lederfolin	Írország, Nagy-Britannia, Olaszország
Ledervorin calcium	Ausztrália, Belgium, Colombia, Egyesült Arab Emírségek, Írország, Lengyelország, Luxemburg, Szaúd-Arábiában
Leucocalcin	Argentína, Chile
Leucovorin	Ausztria, Belgium, Görögország, Lengyelország, Magyarország, Nagy-Britannia, Németország, Svájc, Szlovénia, Törökország
Neofolin	Németország
Novizet	Argentína
Precileucin	Mexikó
Prefolic	Olaszország
Refolinon	Görögország, Nagy-Britannia
Rescuvolin	Belgium, Colombia, Dél-Afrikai Köztársaság, Görögország, Hollandia, Luxemburg, Malaysia, Németország, Svédország
Ribofolin	Ausztria, Irán, Németország
Rontafor	Argentína
Sanficinate	Görögország
Sanifolin	Olaszország
Tecnovorin	Colombia, Peru
Veravorin	Görögország
Xanacanto	Mexikó

Irodalom : Folinate calcium

	Type	Publikáció
73	Napló	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Napló	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
99	Napló	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	Napló	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
155	Napló	Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am J Health-Syst Pharm 1995 ; 52: 710-715.
182	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Napló	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Napló	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
301	Napló	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
479	Napló	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	Napló	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
763	Napló	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
905	Napló	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1287	Napló	Lecompte D, Bousselet M, Gayrard D, Poitou P. Stability study of reconstituted and diluted solutions of calcium folinate. Pharm Ind 1991 ; 53: 90-94.
1410	Napló	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Napló	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Napló	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Napló	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Napló	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1754	Napló	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1914	Laboratórium	Pemetrexed (Alimta®) - Summary of Product Characteristics Eli Lilly 2016
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Napló	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Napló	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2027	Napló	Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222.
2130	Napló	Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J. Stabilité du mélange 5-fluoro-uracil-acide fonique : influence des concentrations, du contenant et de la forme de l’acide folinique. Bull Cancer 1999 ; 86, 11: 946-954.
2181	Napló	Milano G, Renée N. Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. Bull Cancer 1995 ; 82: 189-195.
2295	Laboratórium	Fosaprepitant (Emend®) - Summary of Product Characteristics Merck Sharp Dohme 2013
2340	Napló	Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222.
3474	Laboratórium	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3523	Laboratórium	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3546	Laboratórium	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3619	Laboratórium	Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics Wockhardt 2016
3621	Laboratórium	Phosphate dipotassique - Résumé des caractéristiques du produit Renaudin 2008
3634	Laboratórium	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3694	Napló	Smith J.A, Morris A, Duafala M.E, Bertino J.R, Markman M, Kleinberg M. Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration. Am J Hosp Pharm 1989 ; 46: 985-989.
3753	Laboratórium	Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics Cubist Pharmaceuticals 2014
3838	Laboratórium	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3933	Laboratórium	Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit Teva Laboratoire 2015
4154	Laboratórium	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4720	Laboratórium	Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021. Paratek Pharmaceuticals 2021

Mentions Légales